• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by CureVac N.V.

    1/7/25 5:49:31 PM ET
    $CVAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVAC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001981973
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CureVac N.V.
    SEC File Number
    001-39446
    Address of Issuer
    Friedrich-Miescher-Strasse 15
    Tubingen
    GERMANY
    72076
    Phone
    49707198830
    Name of Person for Whose Account the Securities are To Be Sold
    Myriam Mendila
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    affiliate

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Global Shares Financial Services, Inc
    575 Washington Blvd
    Floor 9
    Jersey City � NJ � 07310-1616
    178398801922431000001/07/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common01/07/2025RSU VestingCureVac (Issuer)Checkbox not checked3485301/08/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    01/07/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/23/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Global Shares Financial Services, Inc, Filing Agent

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVAC

    DatePrice TargetRatingAnalyst
    4/25/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    6/8/2023$13.00Outperform
    SVB Securities
    1/19/2023$8.00 → $18.00Neutral → Buy
    UBS
    1/9/2023$9.00 → $21.00Hold → Buy
    Jefferies
    1/21/2022$55.00 → $20.00Neutral → Underperform
    B of A Securities
    1/18/2022$52.00Market Outperform
    JMP Securities
    10/22/2021$35.00Hold
    Deutsche Bank
    More analyst ratings

    $CVAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

      Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's

      11/4/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Leadership Updates

    Live Leadership Updates

    See more
    • CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

      Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's

      11/4/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

      Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (NASDAQ:CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on Nasdaq and two subsequent follow-on offerings. Under his leadership, CureVac raised over $1.6 billion in equity. Mr. Kemula will succeed Tolga Hassan, who has recently left the company to explore new opportunities closer to home. Follo

      7/11/24 7:00:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Voting Results of General Meeting

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.The shareholders of the Company voted in favor of all proposals. These proposals included the appointment of Thaminda Ramanayake and the reappointment of Malte Greune as members of the Management Board, both effective June 24th, 2024. Additionally, Jean Stéphenne and Mathias Hothum were reappointed as members of the supervisory board, Birgit Hofmann was appointed as a new member of t

      6/24/24 4:20:00 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CureVac downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded CureVac from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      4/25/24 7:53:11 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on CureVac with a new price target

      SVB Securities initiated coverage of CureVac with a rating of Outperform and set a new price target of $13.00

      6/8/23 7:45:44 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac upgraded by UBS with a new price target

      UBS upgraded CureVac from Neutral to Buy and set a new price target of $18.00 from $8.00 previously

      1/19/23 7:20:10 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    SEC Filings

    See more
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      5/23/25 4:03:16 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      5/20/25 4:24:24 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      5/20/25 4:23:16 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Financials

    Live finance-specific insights

    See more
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

      Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board

      8/15/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

      SC 13G/A - CureVac N.V. (0001809122) (Subject)

      2/14/24 5:01:40 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

      SC 13G/A - CureVac N.V. (0001809122) (Subject)

      2/6/24 5:10:10 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CureVac N.V.

      SC 13G - CureVac N.V. (0001809122) (Subject)

      3/27/23 5:00:14 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care